CalciMedica (CALC) insider granted capped warrants for 186,729 shares
Rhea-AI Filing Summary
CalciMedica, Inc. (CALC) reported that its Chief Business Officer and director, Eric W. Roberts, acquired two warrant awards to purchase common stock. Each warrant covers 186,729 shares of common stock, one with an exercise price of $0.8033 per share expiring on December 25, 2027, and another with an exercise price of $1.00 per share expiring on June 25, 2031. Both warrants are exercisable on or after August 19, 2026 and were issued under a Securities Purchase Agreement dated June 23, 2026, approved by an independent board committee. Each warrant includes a 19.99% ownership cap, limiting exercises that would cause the holder and its affiliates to exceed that percentage of CalciMedica’s outstanding common stock, subject to adjustment with 61 days’ notice.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Roberts Eric W
Role
CHIEF BUSINESS OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrant F1, F2 | 186,729 | $0.00 | $0.00 |
| Grant/Award | Warrant F1, F3 | 186,729 | $0.00 | $0.00 |
Holdings After Transaction:
Warrant — 373,458 shares (Direct)
Footnotes (3)
- F1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
- F2. The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.
- F3. The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.
Key Figures
Warrant 1 underlying shares: 186,729 shares
Warrant 1 exercise price: $0.8033 per share
Warrant 1 expiration: December 25, 2027
+5 more
8 metrics
Warrant 1 underlying shares
186,729 shares
Warrant to purchase CalciMedica common stock at $0.8033 per share
Warrant 1 exercise price
$0.8033 per share
Conversion or exercise price for 186,729 underlying shares
Warrant 1 expiration
December 25, 2027
Latest exercise date, subject to earlier IND-clearance trigger
Warrant 2 underlying shares
186,729 shares
Second warrant to purchase CalciMedica common stock at $1.00 per share
Warrant 2 exercise price
$1.00 per share
Conversion or exercise price for 186,729 underlying shares
Warrant 2 expiration
June 25, 2031
Final exercise date for the second warrant
Ownership cap
19.99%
Maximum ownership of CalciMedica common stock including affiliates and attribution parties upon exercise
Notice period to increase ownership cap
61 days
Required notice to raise the beneficial ownership cap percentage
Key Terms
Securities Purchase Agreement, Investigational New Drug Application, U.S. Food and Drug Administration, affiliates and other attribution parties
4 terms
Securities Purchase Agreement financial
"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Investigational New Drug Application regulatory
"following the Issuer's public disclosure of the clearance of its Investigational New Drug Application"
An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.
U.S. Food and Drug Administration regulatory
"clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480"
The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.
affiliates and other attribution parties financial
"the holder, together with its affiliates and other attribution parties, would own more than 19.99%"
FAQ
What insider transaction did CALC disclose for Eric W. Roberts?
CalciMedica disclosed that Eric W. Roberts, its Chief Business Officer and director, received two warrant awards, each covering 186,729 shares of common stock, as acquisitions reported on August 19, 2026 under a Securities Purchase Agreement approved by an independent board committee.
What are the exercise prices of the new CalciMedica (CALC) warrants granted to Eric W. Roberts?
Eric W. Roberts received one warrant with an exercise price of $0.8033 per share and a second warrant with an exercise price of $1.00 per share, each covering 186,729 shares of CalciMedica common stock.
When can the new CALC warrants held by Eric W. Roberts be exercised and when do they expire?
Both warrants may be exercised on or after August 19, 2026. One warrant is exercisable until the earlier of December 25, 2027 or 30 days after public disclosure of IND clearance for CM5480; the other is exercisable until June 25, 2031.
What ownership limitation applies to Eric W. Roberts’ CalciMedica warrants?
Each warrant includes a cap prohibiting exercises that would cause the holder, together with affiliates and attribution parties, to own more than 19.99% of CalciMedica’s outstanding common stock, subject to adjustment to a lower or higher percentage with 61 days’ notice for increases.
How were Eric W. Roberts’ CalciMedica (CALC) warrants approved?
The warrants were acquired from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The agreement and the issuance of the securities were approved by an independent committee of CalciMedica’s Board of Directors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
